These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3713738)

  • 21. Relation between height and clinical course in Duchenne muscular dystrophy.
    Zatz M; Rapaport D; Vainzof M; Rocha JM; Pavanello Rde C; Colletto GM; Peres CA
    Am J Med Genet; 1988 Feb; 29(2):405-10. PubMed ID: 3354613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes of serum creatine kinase levels in children with Duchenne muscular dystrophy].
    Sun SC; Peng YS; He JB
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):35-7. PubMed ID: 18289468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscle and serum enzymes and isoenzymes in muscular dystrophies.
    Ibrahim GA; Zweber BA; Awad EA
    Arch Phys Med Rehabil; 1981 Jun; 62(6):265-9. PubMed ID: 7235920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Screening for elevated creatine kinase activities for the early diagnosis of Duchenne muscular dystrophy].
    Beckmann R; Scheuerbrandt G
    Fortschr Med; 1979 Oct; 97(39):1733-6. PubMed ID: 511067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of carrier detection rates for Duchenne and Becker muscular dystrophies using serum creatine-kinase (CK) and pyruvate-kinase (PK) through discriminant analysis.
    Zatz M; Otto PA
    Am J Med Genet; 1986 Oct; 25(2):219-30. PubMed ID: 3777019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased creatine kinase activity in cultured Duchenne dystrophic muscle cells.
    Iannaccone ST; Nagy B; Samaha FJ
    J Child Neurol; 1987 Jan; 2(1):17-21. PubMed ID: 3624824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cysteine and metalloproteinase activities in serum of Duchenne muscular dystrophic genotypes.
    Sohar I; Laszlo A; Gaal K; Mechler F
    Biol Chem Hoppe Seyler; 1988 May; 369 Suppl():277-9. PubMed ID: 3202967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Identification of the carrier state in the severe recessive X-linked muscular dystrophy (Duchenne type). I. Assay of activated serum creatine kinase activity in serum (author's transl)].
    Rotthauwe HW; Kowalewski S
    Z Kinderheilkd; 1973 Nov; 115(4):333-42. PubMed ID: 4591596
    [No Abstract]   [Full Text] [Related]  

  • 29. [A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children].
    Desnuelle C; Serratrice G; N'guyen VK; Richelme C; Pinsard N
    Arch Fr Pediatr; 1989 Dec; 46(10):759-65. PubMed ID: 2697199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Systematic neonatal screening for Duchenne muscular dystrophy].
    Dellamonica C; Robert JM; Cotte J; Plauchu H; Dorche C
    Nouv Presse Med; 1979 Apr; 8(18):1491-3. PubMed ID: 471723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of preclinical Duchenne muscular dystrophy and its female carriers.
    Beckmann R
    Isr J Med Sci; 1977 Feb; 13(2):102-6. PubMed ID: 863671
    [No Abstract]   [Full Text] [Related]  

  • 32. [Changes in the enzyme activity of muscle tissue in progressive muscular dystrophy].
    Badalian LO; Tamarkina ED; Bondarenko ES; Zakoshchikova LV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(1):72-6. PubMed ID: 5425803
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pathogenesis of pulmonary thrombosis in Duchenne muscular dystrophy; a consideration from changes in serum CK and LDH levels].
    Nakayama T; Saito Y; Uchiyama T; Yatabe K; Kawai M
    Rinsho Shinkeigaku; 2000 Jan; 40(1):55-8. PubMed ID: 10825803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical investigation in Duchenne dystrophy: V. Use of creatine kinase and pyruvate kinase in carrier detection.
    Griggs RC; Mendell JR; Brooke MH; Fenichel GM; Miller JP; Province M; Moxley RT; Huntzinger D; Vaughn A; Cohen M
    Muscle Nerve; 1985 Jan; 8(1):60-7. PubMed ID: 4058458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duchenne muscular dystrophy carrier detection using logistic discrimination: serum creatine kinase and hemopexin in combination.
    Percy ME; Andrews DF; Thompson MW
    Am J Med Genet; 1981; 8(4):397-409. PubMed ID: 7246612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and identification of myoglobin in serum by immunoblotting. Effect of exercise on patients with Duchenne muscular dystrophy.
    Pöche H; Hopfenmüller W; Hoffmann M
    Clin Physiol Biochem; 1987; 5(2):103-11. PubMed ID: 3304774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dantrolene in Duchenne muscular dystrophy.
    Bertorini TE; Palmieri GM; Griffin J; Igarashi M; Hinton A; Karas JG
    Muscle Nerve; 1991 Jun; 14(6):503-7. PubMed ID: 1852156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum creatine kinase in the detection of Duchenne muscular dystrophy carriers: effects of season and multiple testing.
    Percy ME; Andrews DF; Thompson MW
    Muscle Nerve; 1982 Jan; 5(1):58-64. PubMed ID: 7057807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Creatine-kinase (CK) and pyruvate-kinase (PK) activities in cord blood of normal newborn infants: application to Duchenne muscular dystrophy screening programs.
    Passos MR; Zatz M
    Am J Med Genet; 1983 Nov; 16(3):367-72. PubMed ID: 6650572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duchenne muscular dystrophy carrier detection using logistic discrimination: serum creatine kinase, hemopexin, pyruvate kinase, and lactate dehydrogenase in combination.
    Percy ME; Andrews DF; Thompson MW
    Am J Med Genet; 1982 Sep; 13(1):27-38. PubMed ID: 7137219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.